

ASX ANNOUNCEMENT

15 December 2023

Update on Equity Raising

Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) announced on 26 October a capital raise of \$40 million with the issue of two million new ordinary shares (**New Shares**) at \$20 per New Share (**Placement**).

For this placement \$30.8m settled on 1 November 2023 and \$2.5m settled under a second tranche on 15 November 2023. There is a shortfall on the capital raise of \$6.7m due to funds not being received from investors by the final settlement date.

The funds received will be used for preparation for the FDA Pivotal trial of the Company's DurAVR™ THV for treating severe aortic stenosis, continued Valve-in-Valve trials and general working capital expenses.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.



Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Investor Relations (US)

Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Website	www.anteristech.com
Twitter	@AnterisTech
Facebook	www.facebook.com/AnterisTech
LinkedIn	https://www.linkedin.com/company/anteristech

For personal use only

